Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)

NCT03861884 | Recruiting

• 1 other identifier: 18NS001
• Study Type: observational
• Target: 125
• Locations: 1 country
• Sites: 2

Brief Summary

This prospective study aims:

1. 1.to compare cognitive performance in different clinical groups of participants with mild cognitive impairment (MCI) or mild dementia \[Alzheimer's Disease (AD), Vascular Cognitive Impairment (VCI) and Fronto-temporal Dementia (FTD)\] to determine whether scores reveal differential profiles between the groups,
2. 2.to demonstrate differences in imaging markers between different dementia syndromes and healthy volunteers using ultra high-field MRI at 7T.

Conditions

Dementia (Diagnosis)

Outcome Measures

Primary Outcomes (1)

• Neurocognitive scales on Birmingham Cognitive Screen (BCoS) Scores

  cognitive sub scores in relation to clinical phenotype

  Through study completion (an average of one year)

Secondary Outcomes (2)

• Structural imaging changes on MRI at 3T

  Through study completion (an average of one year)

• Susceptibility weighted mapping at 7T

  Through study completion (an average of one year)

Study Arms (3)

Cognitive assessments

Neurocognitive assessments, Birmingham Cognitive Screen

MRI at 3T

Brain Imaging: MRI at 3T

Diagnostic Test: Cognitive assessments

MRI at 7T

Brain imaging: Ultrahigh Field MRI at 7T

Diagnostic Test: Cognitive assessments

Interventions

Cognitive assessments DIAGNOSTIC_TEST

Cognitive assessment and MRI at 3T and/or 7T

Also known as: MRI at 3T, MRI at 7T

MRI at 3T; MRI at 7T

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with Alzheimer's disease, Frontotemporal dementia, Vascular Cognitive Impairment

You may qualify if:

• Ability to give informed consent.
• Either pathological, genetic or imaging biomarker evidence to suggest Fronto-temporal Lobar Degeneration, Alzheimer's Disease or Vascular Cognitive Impairment, or defined clinical diagnoses.

You may not qualify if:

• Lack of mental capacity to consent to study involvement.
• Not speaking English before age 5 years.
• Learning disability.
• MRI contraindications

Sponsors & Collaborators

• Nottingham University Hospitals NHS Trust: lead

Study Sites (2)

Nottinghamshire Healthcare NHS Foundation Trust

Nottingham, Easat Midland, NG7 2TU, United Kingdom

COMPLETED

Nottingham University Hospitals NHS Trust

Nottingham, East Midland, NG7 2UH, United Kingdom

RECRUITING

MeSH Terms

Conditions

Dementia; Disease

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Akram Hosseini, MD, PhD

  Akram.Hosseini@nuh.nhs.uk

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Akram Dr Hosseini

CONTACT

0115 924 9924; Akram.Hosseini@nuh.nhs.uk

Pauline Hyman-Taylor

CONTACT

0115 924 9924; pauline.hyman-taylor@nuh.nhs.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 26, 2019
• First Posted: March 4, 2019
• Study Start: December 12, 2018
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2025
• Last Updated: March 21, 2024

Record last verified: 2024-02

Locations

GB (2)